Remibrutinib Becomes First On-Label Therapy for Symptomatic Dermographism
Remibrutinib, an oral BTK inhibitor, is the first on-label therapy for symptomatic dermographism. David Cotter, MD, PhD, explains what the label changes for prescribers.
Topic
Urticaria
Topic
Urticaria
CIndU Care: Antihistamine Up-Titration Anchors a Still-Gappy Algorithm
CIndU management still hinges on up-titrating H1-antihistamines up to fourfold, but experts flag thin subtype-specific evidence a…
Why Second-Generation H1 Antihistamines Fall Short in CIndU
Second-generation H1 antihistamines leave many chronic inducible urticaria patients uncontrolled, Dermatology Times review finds.
JID Maps Surface Antigens on Mast Cells and Basophils
A Journal of Investigative Dermatology paper published 13 October 2026 profiles homing receptors and activation antigens on human…
Chronic Inducible Urticaria: Epidemiology, Subtypes and QoL Burden Reviewed
Dermatology Times reviews chronic inducible urticaria epidemiology: prevalence, subtype classification, trigger-based diagnosis a…
Chronic Inducible Urticaria: The Quality-of-Life Toll Patients Carry
Patient stories collected by Dermatology Times reveal the hidden quality-of-life burden of chronic inducible urticaria, where eve…
FDA Expands Urticaria Drug Indication to Symptomatic Dermographism
The FDA has expanded a urticaria drug's indication to treat symptomatic dermographism, moving a common inducible urticaria into o…
Barzolvolimab Hits All Phase 3 End Points in Chronic Spontaneous Urticaria
Barzolvolimab, a KIT-targeting monoclonal antibody, met all primary and secondary end points in a Phase 3 chronic spontaneous urt…